healthliberal
The Push and Pull of Orphan Drug Availability
WORLDWIDEMonday, December 16, 2024
Governments are chipping in with subsidies, and pharmaceutical companies are setting aside special budgets for research. Biotechnology is making leaps, and corporate social responsibility is nudging companies to care about these rare diseases. As more people learn about and can diagnose these diseases, awareness is growing.
A study looked into these factors and how they affect each other. With help from experts, they found that tech, laws, support groups, and budgets are the main drivers. On the other side, awareness, diagnosis, drug availability, subsidies, CSR, and biotech are the results of these efforts.
Actions
flag content